{"entity":{"id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","aka":[],"tldr":"A phase 1/2 trial of Peluntamig, Carboplatin, Etoposide in small-cell lung cancer and prostate cancer, run by Phanes Therapeutics, now recruiting.","summary":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) is a phase 1/2 interventional study registered as NCT05652686 by Phanes Therapeutics, with 203 participants planned, started 2023-09-05 and due to reach its primary completion in 2027-12. Interventions recorded: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin. Conditions listed: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05652686","url":"https://clinicaltrials.gov/study/NCT05652686"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["peluntamig","carboplatin","etoposide","paclitaxel","atezolizumab","lurbinectedin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05652686","phase":"1/2","setting":"An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)","sponsor":"Phanes Therapeutics","enrolled":203,"outcomes":[]},"route":"/trials/nct05652686/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/"}]}}